Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10394481 | 0.83 | TSHR (0.40) | — | |
| SCHEMBL10395348 | 0.83 | CTSA (0.37) | — | |
| SCHEMBL10394488 | 0.79 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL4906192 | 0.78 | — | — | |
| SCHEMBL29171612 | 0.78 | — | — | |
| SCHEMBL10586380 | 0.78 | — | — | |
| SCHEMBL10395370 | 0.77 | CTSA (0.37) | — | |
| SCHEMBL10395233 | 0.77 | TSHR (0.40) | — | |
| SCHEMBL10395279 | 0.76 | CYP3A4 (0.48) | ALDH1A1 | |
| SCHEMBL11340495 | 0.75 | ALDH1A1 (0.33) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114891038-A | Phosphoantigen compound, method for producing the same, and culture method for Vgamma 9 Vdelta 2T cells | 珠海善行免疫微生态产业研究院有限公司 | 2022-08-12 | — | — | CN | claimed |
| US-4820698-A | TETRAALKYL ETHENYLIDENEBISPHOSPHONATES | THE PROCTER & GAMBLE COMPANY (US) | 1989-04-11 | — | — | US | claimed |
| EP-0221611-A2 | Antimicrobial agents and process for their manufacture | THE PROCTER & GAMBLE COMPANY (US) | 1987-05-13 | — | — | EP | claimed |
| CN-114891038-A | Phosphoantigen compound, method for producing the same, and culture method for Vgamma 9 Vdelta 2T cells | 珠海善行免疫微生态产业研究院有限公司 | 2022-08-12 | — | — | CN | disclosed |
| US-20220002576-A1 | GAS-ACTIVATED CYANOACRYLATES FOR 3-D PRINTING | HENKEL AG & CO KGAA (DE) | 2022-01-06 | — | — | US | disclosed |
| WO-2020187548-A1 | GAS-ACTIVATED CYANOACRYLATES FOR 3D-PRINTING | HENKEL AG & CO. KGAA (DE) | 2020-09-24 | — | — | WO | disclosed |
| EP-3708370-A1 | 3D-PRINTING METHOD USING GAS-ACTIVATED CYANOACRYLATES | Henkel AG & Co. KGaA (DE) | 2020-09-16 | — | — | EP | disclosed |
| EP-3235822-B1 | NOVEL BISPHOSPHONIC ACID DERIVATIVE AND APPLICATION FOR SAME | UNIV NAGASAKI (JP) | 2020-01-29 | — | — | EP | disclosed |
| US-20170360811-A1 | NOVEL BISPHOSPHONIC ACID DERIVATIVE AND APPLICATION FOR SAME | NAGASAKI UNIVERSITY (JP) | 2017-12-21 | — | — | US | disclosed |
| US-20170360811-A1 | NOVEL BISPHOSPHONIC ACID DERIVATIVE AND APPLICATION FOR SAME | NAGASAKI UNIVERSITY (JP) | 2017-12-21 | — | — | US | disclosed |
| US-20170360811-A1 | NOVEL BISPHOSPHONIC ACID DERIVATIVE AND APPLICATION FOR SAME | NAGASAKI UNIVERSITY (JP) | 2017-12-21 | — | — | US | disclosed |
| US-20040206932-A1 | Compositions including polymerizable bisphosphonic acids and methods | 3M INNOVATIVE PROPERTIES COMPANY | 2004-10-21 | — | — | US | disclosed |
| WO-2004060327-A1 | COMPOSITIONS INCLUDING POLYMERIZABLE BISPHOSPHONIC ACIDS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-07-22 | — | — | WO | disclosed |
| CN-1031826-C | Pyrazolopyrimidine and pyrimidinyl bisphosphonic esters as anti-inflammatories | UPJOHN CO (US) | 1996-05-22 | — | — | CN | disclosed |
| CN-1119941-A | Use of purimifdinyl bisphophonic esters for the preparation of a medicament for treating of inflammatin | UPJOHN CO (US) | 1996-04-10 | — | — | CN | disclosed |
| CN-1068332-A | Pyrazolopyrimidine and pyrimidinyl two phosphonate as antiphlogiston | UPJOHN CO (US) | 1993-01-27 | — | — | CN | disclosed |
| US-4939284-A | Process for the manufacture of tetraalkyl ethenylidenebisphosphonate esters | THE PROCTER & GAMBLE COMPANY (US) | 1990-07-03 | — | — | US | disclosed |
| US-4820698-A | TETRAALKYL ETHENYLIDENEBISPHOSPHONATES | THE PROCTER & GAMBLE COMPANY (US) | 1989-04-11 | — | — | US | disclosed |
| EP-0221611-A2 | Antimicrobial agents and process for their manufacture | THE PROCTER & GAMBLE COMPANY (US) | 1987-05-13 | — | — | EP | disclosed |
| US-4246103-A | INHIBIT PRECIPITATION OF HARD WATER IONS ESPECIALLY FOR INDUSTRIAL WATER AND SLUDGE | BAYER AKTIENGESELLSCHAFT (DE) | 1981-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360811-A1 | NOVEL BISPHOSPHONIC ACID DERIVATIVE AND APPLICATION FOR SAME | BPGM, PMM2, PGM2 | ALDH1A1 3793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.